Citations 3

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1

Autophagy | March 24, 2021 | Volume: 17 | Issue: 1 | Pages: 1-382

10.1080/15548627.2020.1797280 | PMID 33634751

Dynamics of pulse wave velocity and vascular augmentation index in association with endothelial progenitor cells in SLE

Lupus Science & Medicine | December 24, 2016 | Volume: 3 | Issue: 1 | Pages: e000185

10.1136/lupus-2016-000185 | PMID 28176918

Patients with SLE display a significantly higher cardiovascular risk (CVR). Pulse wave velocity (PWV) has meanwhile been established as a reliable parameter of end-organ damage. Endothelial progenitor cells (EPCs) are critically involved in vascular repair under both physiological and pathological conditions. The aim of the study was to analyse PWV and the Vascular Augmentation Index (VAI) and EPC numbers/regeneration in a well-defined German SLE cohort. Thirty patients were included. Only two individuals displayed a PWV of above 10 m/s. There was no correlation between PWV percentiles and disease activity as reflected by the SLE Disease Activity Index. Neither EPC colonies nor percentages of circulating EPCs (CD133+/KDR+) correlated with PWV/VAI in a positive or negative manner. Thus, it can be questioned whether pulse wave analysis and/or EPC proliferation and circulating cell numbers are truly useful for CVR assessment in SLE.
Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman

Lupus | September 7, 2013 | Volume: 22 | Issue: 14 | Pages: 1523-1525

10.1177/0961203313504145 | PMID 24014569

We report the case of a 19-year-old woman with progressive proliferative lupus nephritis (LN) class III after induction and maintenance therapy with mycophenolate mofetil (MMF). Despite a satisfying clinical improvement proteinuria progressed under this medication. We treated the patient with additional belimumab after discussing other options. Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. Belimumab might hold promise for this indication.